CBER Considers Allowing Cross-Supplemental Claims For NAT Assays
This article was originally published in The Gray Sheet
Executive Summary
FDA's Center for Biologics Evaluation and Research (CBER) may issue a guidance establishing criteria for using nucleic acid tests as supplemental, confirmatory tests following initial NAT blood screening